Randomized trial · people
Tesamorelin shifted liver gene activity in HIV-related fatty liver
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with HIV and fatty liver, the liver benefits seen with tesamorelin in this trial came with matching changes in liver gene activity, including lower inflammation-related genes.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2020
- Journal
- JCI Insight
What they tested
The team wanted to see which liver gene pathways tesamorelin changes, compared with placebo, in people with HIV who have NAFLD (nonalcoholic fatty liver disease).
How the study was done
A follow-up analysis of a randomized, placebo-controlled 1-year trial in people with HIV and NAFLD, in which tesamorelin had lowered liver fat and kept scarring (fibrosis) from getting worse. The researchers compared paired liver biopsies, taken from the same people, using gene set enrichment analysis, a method that tests whether whole groups of related genes move together.

What they found
Compared with placebo, tesamorelin raised the activity of gene sets tied to oxidative phosphorylation, a cell energy process. It lowered gene sets tied to inflammation, tissue repair and cell division. It also pushed up gene sets linked to a better outlook in hepatocellular carcinoma (a liver cancer) and pushed down those linked to a worse outlook. In the tesamorelin group, these shifts tracked with a better fibrosis-related gene score.
What it doesn’t show
This is a secondary look at gene activity in liver tissue, not a new test of clinical outcomes, and the gene changes are signals rather than proof of health effects. It included only people with HIV-related NAFLD.
The paper
Fourman et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Tesamorelin cut visceral fat 15.4% vs placebo in HIV at 26 weeksRandomized trial · people · 2010
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.